Zentalis (ZNTL) Locks In Its Cancer Drug Dose; Jefferies Raises the Target
Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) is one of the must-buy small cap stocks to buy. On April 10, Jefferies raised its price target on Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) from $2.50 to $6.00 and left the Hold rating unchanged. This decision came after Zentalis said it had selected the optimal dose of its lead cancer drug azenosertib based on interim data from an ongoing clinical trial. Zentalis (ZNTL) Locks In Its Cancer Drug Dose; Jefferies Raises the Target Zentalis announced in an April 9 ...